Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.

Research output: Contribution to journalArticle


Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) with high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft Internistische Onkologie) trial. To investigate whether the survival benefits have persisted, we performed the second planned analysis of the trial.


  • Heikki Joensuu
  • Mikael Eriksson
  • Kirsten Sundby Hall
  • Annette Reichardt
  • Jörg T Hartmann
  • Daniel Pink
  • Giuliano Ramadori
  • Peter Hohenberger
  • Salah-Eddin Al-Batran
  • Marcus Schlemmer
  • Sebastian Bauer
  • Eva Wardelmann
  • Bengt Nilsson
  • Harri Sihto
  • Petri Bono
  • Raija Kallio
  • Jouni Junnila
  • Thor Alvegård
  • Peter Reichardt
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)244-250
JournalJournal of Clinical Oncology
Issue number3
Early online date2015 Nov 2
Publication statusPublished - 2016
Publication categoryResearch